| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | MSI2H; MGC3245; MSI2;;MSI2 |
| WB Predicted band size | 35 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human MSI2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3-4篇关于 **MSI2抗体** 的参考文献及其摘要概括：
---
1. **文献名称**: *Musashi2 sustains colorectal cancer stemness by suppressing p21 through direct binding to CDK6*
**作者**: Li N, et al.
**摘要**: 本研究通过免疫组化(使用MSI2特异性抗体)发现MSI2在结直肠癌中高表达，且与患者预后不良相关。实验表明，MSI2通过结合CDK6抑制p21表达，维持肿瘤干性，促进化疗耐药。
---
2. **文献名称**: *MSI2 is required for maintaining self-renewal of human glioblastoma stem cells*
**作者**: Wang XY, et al.
**摘要**: 研究利用MSI2抗体在胶质母细胞瘤中验证其蛋白表达，发现敲低MSI2可显著抑制肿瘤干细胞自我更新能力，并降低Notch信号通路活性，提示MSI2作为潜在治疗靶点。
---
3. **文献名称**: *Musashi2 modulates K562 leukemic cell proliferation through post-transcriptional regulation of c-KIT and p53*
**作者**: Park SM, et al.
**摘要**: 通过Western blot和免疫荧光(使用抗MSI2抗体)，作者发现MSI2通过结合c-KIT和p53的mRNA调控其翻译，促进白血病细胞增殖，并参与伊马替尼耐药机制。
---
4. **文献名称**: *MSI2 as a prognostic biomarker in hepatocellular carcinoma*
**作者**: Chen S, et al.
**摘要**: 该研究通过组织微阵列和MSI2抗体检测肝癌样本，证实MSI2高表达与肿瘤转移及患者生存期缩短相关，并揭示其通过Wnt/β-catenin通路促进肝癌进展。
---
以上文献均涉及MSI2抗体在癌症机制或临床诊断中的应用，涵盖蛋白功能验证、分子机制及预后评估等领域。如需具体期刊信息或年份，可进一步补充检索条件。
The Musashi homolog 2 (MSI2) antibody is a tool used to detect and study the MSI2 protein, a member of the RNA-binding protein family critical for post-transcriptional gene regulation. MSI2 contains two RNA recognition motifs (RRMs) that bind to target mRNAs, influencing their stability, translation, or localization. It is highly expressed in stem and progenitor cells, where it maintains self-renewal and inhibits differentiation by repressing tumor suppressor pathways (e.g., NUMB/Notch signaling). Dysregulation of MSI2 is linked to cancer progression, particularly in aggressive malignancies like leukemia, glioblastoma, and solid tumors, where it promotes tumor initiation, metastasis, and therapy resistance.
MSI2 antibodies are essential for investigating its expression patterns, functional roles, and interactions in both normal development and disease contexts. These antibodies enable techniques such as Western blotting, immunohistochemistry, and immunofluorescence, aiding in biomarker discovery and therapeutic targeting. Research highlights MSI2 as a prognostic indicator and potential therapeutic target, with studies showing its overexpression correlates with poor clinical outcomes. However, challenges remain in understanding tissue-specific isoforms and context-dependent regulatory mechanisms. Overall, MSI2 antibodies serve as vital reagents for unraveling its contributions to cellular plasticity and oncogenesis.
×
